Personne :
Doillon, Charles

Photo de profil
Adresse électronique
Date de naissance
Projets de recherche
Structures organisationnelles
Fonction
Nom de famille
Doillon
Prénom
Charles
Affiliation
Centre Hospitalier de l'Université Laval (CHUL), Faculté de médecine, Université Laval
ISNI
ORCID
Identifiant Canadiana
ncf11847055
person.page.name

Filtres

20151
Réinitialiser les filtres

Paramètres

Résultats de recherche

Voici les éléments 1 - 1 sur 1
  • Publication
    Restreint
    Synergistic control of sex hormones by 17b-HSD type 7 : a novel target for estrogen-dependent breast cancer
    (Oxford University Press, 2015-05-12) Poirier, Donald; Wang, Xiao Qiang; Gérard, Catherine; Lin, Sheng-Xiang; Doillon, Charles; Thériault, Jean-François
    17b-hydroxysteroid dehydrogenase (17b-HSD) type 1 is known as a critical target to block the final step of estrogen production in estrogen-dependent breast cancer. Recent confirmation of the role of dyhydroxytestosterone (DHT) in counteracting estrogen induced cell growth prompted us to study the reductive 17b-HSD type 7 (17b-HSD7), which activates estrone while markedly inactivating DHT. The role of DHTin breast cancer cell proliferationis demonstrated by its independent suppression of cell growth in the presence of a physiological concentration of estradiol (E2). Moreover, an integral analysis of a large number of clinical samples in Oncomine datasets demonstrated the overexpression of 17b-HSD7 in breast carcinoma. Inhibition of 17b-HSD7 in breast cancer cells resulted in a lower level of E2 and a higher level of DHT, successively induced regulation of cyclinD1, p21, Bcl-2, and Bik, consequently arrested cell cycle in the G0/G1 phase, and triggered apoptosis and auto-downregulation feedback of the enzyme. Such inhibition led to significant shrinkage of xenograft tumors with decreased cancer cell density and reduced 17b-HSD7 expression. Decreased plasma E2 and elevated plasma DHT levels were also found. Thus, the dual functional 17b-HSD7 is proposed as a novel target for estrogen-dependent breast cancer by regulating the balance of E2 and DHT. This demonstrates a conceptual advance on the general belief that the major role of this enzyme is in cholesterol metabolism.